Harmony Biosciences Holdings Inc
HRMY34.840USD
+0.440+1.28%
Market hours （ET）Quotes delayed by 15 min
2.00BMarket Cap
13.09P/E TTM
More Details of Harmony Biosciences Holdings Inc Company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
Ticker SymbolHRMY
Company nameHarmony Biosciences Holdings Inc
IPO dateAug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 19
Address630 W Germantown Pike
CityPLYMOUTH MEETING
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code19462
Phone14845399800
Websitehttps://www.harmonybiosciences.com/
Ticker SymbolHRMY
IPO dateAug 19, 2020
CEODr. Jeffrey M. (Jeff) Dayno, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Mark Graf
Mr. R. Mark Graf
Independent Director
Independent Director
--
--
Mr. Gary L. Sender
Mr. Gary L. Sender
Independent Director
Independent Director
--
--
Dr. Jeffrey M. (Jeff) Dayno, M.D.
Dr. Jeffrey M. (Jeff) Dayno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Anastasiou
Mr. Peter Anastasiou
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
184.73M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Valor Equity Partners
11.52%
Marshman Fund Trust ii
10.54%
BlackRock Institutional Trust Company, N.A.
9.78%
Fidelity Management & Research Company LLC
9.30%
The Vanguard Group, Inc.
8.17%
Other
50.69%
Shareholders
Shareholders
Proportion
Valor Equity Partners
11.52%
Marshman Fund Trust ii
10.54%
BlackRock Institutional Trust Company, N.A.
9.78%
Fidelity Management & Research Company LLC
9.30%
The Vanguard Group, Inc.
8.17%
Other
50.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.36%
Investment Advisor/Hedge Fund
20.39%
Private Equity
12.38%
Corporation
10.54%
Hedge Fund
7.28%
Research Firm
3.33%
Sovereign Wealth Fund
0.97%
Pension Fund
0.96%
Venture Capital
0.68%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
550
60.09M
104.65%
-11.51M
2025Q1
573
60.17M
104.79%
-12.54M
2024Q4
571
62.71M
109.35%
-5.92M
2024Q3
559
64.22M
112.66%
-9.33M
2024Q2
548
64.68M
113.76%
-9.02M
2024Q1
546
63.23M
110.16%
-590.81K
2023Q4
534
62.18M
105.68%
-302.40K
2023Q3
502
63.52M
115.31%
-874.73K
2023Q2
488
66.12M
110.24%
+3.64M
2023Q1
470
65.39M
109.09%
+5.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Valor Equity Partners
6.62M
11.52%
--
--
Mar 31, 2025
Marshman Fund Trust ii
6.05M
10.54%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.62M
9.78%
-354.88K
-5.94%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.34M
9.3%
+12.62K
+0.24%
Mar 31, 2025
The Vanguard Group, Inc.
4.69M
8.17%
-34.26K
-0.73%
Mar 31, 2025
HBM Partners AG
2.15M
3.74%
--
--
Mar 17, 2025
State Street Global Advisors (US)
1.58M
2.75%
-1.78K
-0.11%
Mar 31, 2025
American Century Investment Management, Inc.
1.29M
2.24%
+186.18K
+16.89%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.22M
2.13%
+11.77K
+0.97%
Mar 31, 2025
LSV Asset Management
1.19M
2.08%
+238.74K
+24.97%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
2.77%
Invesco Pharmaceuticals ETF
2.53%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.96%
Virtus LifeSci Biotech Products ETF
1.83%
Euclidean Fundamental Value ETF
1.57%
Invesco S&P SmallCap 600 GARP ETF
1.17%
First Trust Small Cap US Equity Select ETF
1.1%
Lattice Hartford Multifactor Small Cap ETF
1.06%
ETC 6 Meridian Small Cap Equity ETF
1.05%
VictoryShares Small Cap Free Cash Flow ETF
0.88%
View more
SPDR S&P Pharmaceuticals ETF
Proportion2.77%
Invesco Pharmaceuticals ETF
Proportion2.53%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.96%
Virtus LifeSci Biotech Products ETF
Proportion1.83%
Euclidean Fundamental Value ETF
Proportion1.57%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.17%
First Trust Small Cap US Equity Select ETF
Proportion1.1%
Lattice Hartford Multifactor Small Cap ETF
Proportion1.06%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.05%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.88%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
